For example, only 1.1% of patients in the CHAMP-HF registry received triple therapy at target doses for renin–angiotensin–aldosterone system (RAAS) inhibitors, beta-blockers, and mineralocorticoid receptor antagonists [21]. This evidence concerns the gene NR3C2 and hydrops fetalis.